The observation of animal orofacial and behavioral reactions has played a fundamental role in research on reward but is seldom assessed in humans. Healthy volunteers (N = 131) received 400 mg of the dopaminergic antagonist amisulpride, 50 mg of the opioidergic antagonist naltrexone, or placebo. Subjective ratings, physical effort, and facial reactions to matched primary social (affective touch) and nonsocial (food) rewards were assessed. Both drugs resulted in lower physical effort and greater negative facial reactions during reward anticipation, especially of food rewards. Only opioidergic manipulation through naltrexone led to a reduction in positive facial reactions to liked rewards during reward consumption. Subjective ratings of wanting and liking were not modulated by either drug. Results suggest that facial reactions during anticipated and experienced pleasure rely on partly different neurochemical systems, and also that the neurochemical bases for food and touch rewards are not identical.
Partial lying denotes the cases where we partially believe something to be false but nevertheless assert it with the intent to deceive the addressee. We investigate how the severity of partial lying may be determined and how partial lies can be classified. We also study how much epistemic damage an agent suffers depending on the level of trust that she invests in the liar and the severity of the lies she is told. Our analysis is based on the results from exploratory computer simulations of an arguably rational Bayesian agent who is trying to determine how biased a coin is while observing the coin tosses and listening to a (partial) liar's misleading predictions about the outcomes. Our results provide an interesting testable hypothesis at the intersection of epistemology and ethics, namely that in the longer term partial lies lead to more epistemic damage than outright lies.If falsehood had, like truth, but one face only, we should be upon better terms; for we should then take for certain the contrary to what the liar says: but the reverse of truth has a hundred thousand forms, and a field indefinite, without bound or limit (Montaigne).
Rewards are a broad category of stimuli inducing approach behavior to aid survival. Extensive evidence from animal research has shown that wanting (the motivation to pursue a reward) and liking (the pleasure associated with its consumption) are mostly regulated by dopaminergic and opioidergic activity in dedicated brain areas. However, less is known about the neuroanatomy of dopaminergic and opioidergic regulation of reward processing in humans, especially when considering different types of rewards (i.e., social and non-social). To fill this gap of knowledge, we combined dopaminergic and opioidergic antagonism (via amisulpride and naltrexone administration) with functional neuroimaging to investigate the neurochemical and neuroanatomical bases of wanting and liking of matched non-social (food) and social (interpersonal touch) rewards, using a randomized, between-subject, placebo-controlled, double-blind design. While at the behavioral level no drug effect was observed, brain activity was modulated by the administered compounds. In particular, opioid antagonism, compared to placebo, was associated with reduced activity in the medial orbitofrontal cortex during consumption of the most valued social and non-social rewards. Dopamine antagonism, however, had no clear effects on brain activity in response to rewards anticipation. These findings provide insights into the neurobiology of human reward processing and suggest a similar opioidergic regulation of the neural responses to social and non-social reward consumption.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.